157 related articles for article (PubMed ID: 15557913)
1. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis.
Ouriel K; Kaul AF; Leonard MC
J Vasc Surg; 2004 Nov; 40(5):971-7. PubMed ID: 15557913
[TBL] [Abstract][Full Text] [Related]
2. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
Sugimoto K; Hofmann LV; Razavi MK; Kee ST; Sze DY; Dake MD; Semba CP
J Vasc Surg; 2003 Mar; 37(3):512-7. PubMed ID: 12618684
[TBL] [Abstract][Full Text] [Related]
3. The association of periprocedural hypertension and adverse outcomes in patients undergoing catheter-directed thrombolysis.
Agle SC; McNally MM; Powell CS; Bogey WM; Parker FM; Stoner MC
Ann Vasc Surg; 2010 Jul; 24(5):609-14. PubMed ID: 20413257
[TBL] [Abstract][Full Text] [Related]
4. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators.
Ouriel K; Veith FJ; Sasahara AA
N Engl J Med; 1998 Apr; 338(16):1105-11. PubMed ID: 9545358
[TBL] [Abstract][Full Text] [Related]
5. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis.
Ouriel K; Gray B; Clair DG; Olin J
J Vasc Interv Radiol; 2000 Mar; 11(3):295-8. PubMed ID: 10735422
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion.
Shortell CK; Queiroz R; Johansson M; Waldman D; Illig KA; Ouriel K; Green RM
J Vasc Surg; 2001 Nov; 34(5):854-9. PubMed ID: 11700486
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes.
Kim HS; Patra A; Paxton BE; Khan J; Streiff MB
J Vasc Interv Radiol; 2006 Jul; 17(7):1099-104. PubMed ID: 16868161
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolytic agents for peripheral arterial occlusion.
Robertson I; Kessel DO; Berridge DC
Cochrane Database Syst Rev; 2013 Dec; (12):CD001099. PubMed ID: 24357258
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic agents for peripheral arterial occlusion.
Robertson I; Kessel DO; Berridge DC
Cochrane Database Syst Rev; 2010 Mar; (3):CD001099. PubMed ID: 20238313
[TBL] [Abstract][Full Text] [Related]
10. Treatment for peripheral arterial obstructive disease: An appraisal of the economic outcome of complications.
Flu H; van der Hage JH; Knippenberg B; Merkus JW; Hamming JF; Lardenoye JW
J Vasc Surg; 2008 Aug; 48(2):368-376. PubMed ID: 18502082
[TBL] [Abstract][Full Text] [Related]
11. Catheter-directed thrombolysis with percutaneous rheolytic thrombectomy versus thrombolysis alone in upper and lower extremity deep vein thrombosis.
Kim HS; Patra A; Paxton BE; Khan J; Streiff MB
Cardiovasc Intervent Radiol; 2006; 29(6):1003-7. PubMed ID: 16967220
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and cost of deep venous thrombosis among patients with cancer.
Elting LS; Escalante CP; Cooksley C; Avritscher EB; Kurtin D; Hamblin L; Khosla SG; Rivera E
Arch Intern Med; 2004 Aug 9-23; 164(15):1653-61. PubMed ID: 15302635
[TBL] [Abstract][Full Text] [Related]
13. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
Grunwald MR; Hofmann LV
J Vasc Interv Radiol; 2004 Apr; 15(4):347-52. PubMed ID: 15064337
[TBL] [Abstract][Full Text] [Related]
14. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial.
Meyerovitz MF; Goldhaber SZ; Reagan K; Polak JF; Kandarpa K; Grassi CJ; Donovan BC; Bettmann MA; Harrington DP
Radiology; 1990 Apr; 175(1):75-8. PubMed ID: 2107563
[TBL] [Abstract][Full Text] [Related]
15. Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity.
Grewal NK; Martinez JT; Andrews L; Comerota AJ
J Vasc Surg; 2010 May; 51(5):1209-14. PubMed ID: 20347543
[TBL] [Abstract][Full Text] [Related]
16. Cerebral venous congestion as indication for thrombolytic treatment.
Tsai FY; Kostanian V; Rivera M; Lee KW; Chen CC; Nguyen TH
Cardiovasc Intervent Radiol; 2007; 30(4):675-87. PubMed ID: 17573553
[TBL] [Abstract][Full Text] [Related]
17. Thrombolytic therapy for arterial occlusion: a mixed blessing.
Smith CM; Yellin AE; Weaver FA; Li KM; Siegel AE
Am Surg; 1994 May; 60(5):371-5. PubMed ID: 8161090
[TBL] [Abstract][Full Text] [Related]
18. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
19. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions.
Schweizer J; Altmann E; Stösslein F; Florek HJ; Kaulen R
Eur J Radiol; 1996 May; 22(2):129-32. PubMed ID: 8793432
[TBL] [Abstract][Full Text] [Related]
20. Intra-arterial urokinase versus surgery for acute peripheral arterial occlusion.
Neudeck BL; Blumenschein K; Endean ED; Loh FK; Rapp RP
Am J Health Syst Pharm; 1997 Sep; 54(17):1963-8. PubMed ID: 9290893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
